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compensated by another, functionally overlapping DDR 
pathway whose activity may be increased, causing resistance 
to DNA-damaging radiotherapy and chemotherapy. Therefore, 
the DDR response makes an ideal target for therapeutic 
intervention by preventing or reversing therapy resistance or 
by using a synthetic lethality approach to specifically kill 
cancer cells that are dependent on a compensatory DNA 
repair pathway for survival in the context of cancer-
associated oxidative and replicative stress. However, in the 
context of DNA replication several DNA repair pathways are 
gathered with overlapping functions, as demonstrated by the 
synthetic lethal interaction between the DNA double strand 
repair pathway homologous recombination (HR) and the base 
excision repair pathway (BER) as well as between checkpoint 
signaling (ATR/CHK1) and the Fanconi anaemia pathway. As 
the number of inhibitors that target components of these 
pathways expands the potential for using these synthetic 
lethal interactions increases, provided that the exploitable 
defects in the tumour can be identified with suitable 
biomarkers. These hypotheses are currently being tested in 
the laboratory and translated into clinical studies. 
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Introduction - Anal cancer is a rare disease but its incidence 
is rising rapidly. The majority of tumours are squamous cell 
carcinoma or its histological variants. Despite its rarity phase 
III clinical trials have been successfully performed. The “first 
generation” of phase III trials tested the benefit of 
concurrent chemotherapy when added to radiotherapy. This 
led to Mitomycin C 5Fluorouracil and radiotherapy (CRT) 
becoming the standard of care. The shift from radical surgery 
with permanent stoma to non-surgical combined modality 
treatment was achieved through these clinical trials and 
recent published evidence confirms the impact on population 
based practice. The “second generation” of phase III did not 
change the standard of care. They demonstrated no benefit 
from the addition of neoadjuvant or maintenance 
chemotherapy to CRT and no improvement in outcome from 
the use of cisplatin based CRT. The ESMO-ESSO-ESTRO and 
NCCCN guidelines provide evidence based recommendations 
for the management of anal cancer and aspects of the 
guidelines will be reviewed during this teach lecture.  
Staging – Whilst it is important to identify the relatively small 
minority of patients who present with synchronous metastatic 
disease, the main role of imaging is to determine the extent 
of disease in the pelvis prior to CRT. Although pelvic MR is 
not mandated in the guidelines it provides superior 
anatomical images of the primary tumour which is very 
helpful for conventional CT planning and delineation of the 
gross tumour volume. CT-PET is also not mandated but is 
shown to upstage a minority of patients from a “N0” category 
to “N+.” Examples of this will be presented and discussed. 
Radiotherapy dose fractionation – there is wide variation in 
the prescribed radiotherapy dose to both gross tumour 
volume and clinical target volumes. Many centres will use 
higher doses of 60Gy or greater to more advanced tumours. 
However, to date randomized clinical trials have not 
demonstrated any clear benefit for dose escalation. There is 
also a paucity of late toxicity and patient reported outcome 
data to determine the impact of such an approach.  
Radiotherapy technique and target volume definition - The 
use of IMRT has significantly increased in the treatment of 
anal cancer and its use is supported by the RTOG 0529 phase 
II trial. Although IMRT may be preferred and will reduce 
acute genital toxicity, careful target volume definition and 
delineation of organs at risk and high quality QA are required 
to ensure accurate treatment delivery. The AGITG contouring 
atlas has been very helpful to clinicians. The UK approach to 
introducing IMRT will be discussed.  
Response assessment - Clinical and radiological assessment 
is required to both identify early local treatment failures and 
to establish whether complete response had been achieved. 
The European guidelines recommend assessment at 11, 18 
and 26 weeks from the start of CRT. Recent published data 
will be reviewed. The optimal timing and imaging is the 
subject for further research.  
Follow up - Most centres will review patients at least three 
monthly in the first two years, with approximately 80% of 
pelvic recurrences occurring during this period. The duration 
of follow up and the intensity of imaging varies widely.  
Late toxicity - Although it is assumed that most patients will 
experience improved quality of life with CRT rather than 
radical surgery there is limited data on the impact of late 
radiotherapy effects on patients. New data is required 
particularly with the use of IMRT to understand this in more 
detail. An anal cancer specific module quality of life module 
is in development through the EORTC.  
Treatment of metastatic disease - Approximately 10-20% of 
patients will develop metastatic disease. There is no 
consensus on the best first or second line chemotherapy 
regimens and reports of the outcomes following surgical or 
non surgical treatment of oligometastatic disease are sparse. 
The InterAAcT trial is an international randomized phase II 
study comparing cisplatin 5FU with Carboplatin and Paclitaxel 
and will be discussed  
Future research - Future clinical trials will provide more 
information on outcome and late toxicity with the use of 
IMRT. The UK led PLATO trial consortium are conducting a 
“platform” type trial with the ACT3 ACT4 and ACT5 trials 
addressing specific research questions. ACT3 evaluates a 
selective use of reduced dose CRT for patients with T1N0 
anal margin tumours; ACT 4 will compare standard versus 
lower dose CRT for early stage disease; ACT5 will test two 
IMRT SIB dose escalation CRT schedules against standard dose 
CRT. 
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The immunosuppressive effects of radiation therapy have 
long been the only one considered. Dying cancer cell may 
release signals which activate the surrounding immune cells, 
namely through the immunological cell death process. 
Irradiation can also increase the diversity of tumor neo 
antigens which are crucial to the induction of adaptive 
antitumor immunity. It has recently been shown that the 
inhibition of immune inhibitory checkpoints synergizes with 
ionizing radiation in preclinical models. Hypoxia is one of the 
key factors influencing clinical outcome after radiotherapy 
responsible for reduced local control that will influence 
overall survival, as may the hypoxic conditions by increasing 
malignant progression. For decades, hypoxia was thought to 
act primarily on tumor cells resistance, namely the number 
of clonogenic cancer stem cells surviving after radiation 
treatment. Increased cellular turnover and hypoxia promote 
the production and release of large amounts of 
immunosupressive adenosine into the local 
microenvironment. Hypoxia can induce HIF-1a-dependent 
expression of arginase-1 and M2 polarization of macrophages. 
Recent data suggest that the immune contexture of tumors 
might be correlated with outcome after irradiation. The 
purpose of tumor immunotherapy is based on the principle 
that reversal of tolerance to immunogenic tumors would be 
able to activate an immune response against tumor cells. The 
importance of the immune component into the process of 
tumor response to radiation offers novel opportunities for 
therapeutic interventions. 
 
 
 
